{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:39:44Z","timestamp":1754163584558,"version":"3.41.2"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Prior studies have evaluated the level of evidence behind treatment options listed in the National Comprehensive Cancer Network (NCCN) guidelines, but no study has categorized the life cycle of regimens listed in the NCCN guidelines. We longitudinally assessed the life cycle for each regimen for newly diagnosed multiple myeloma. We track the date of first clinical data, the date of regimen addition to NCCN guidelines, the date phase 3 data (if performed) were reported, and the results of phase 3 trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically examined NCCN guidelines from January 2000 to April 2021. The primary objective of our study was to assess the life cycle of each drug\/regimen listed on the NCCN guidelines. We systematically examined the following aspects for each regimen: (1) the inception of prospective clinical data, (2) its inclusion in the NCCN guidelines, (3) the completion of a randomized trial (if done), (4) the presence of an overall survival benefit in such trials, and (5) the removal of a regimen from NCCN guidelines (if done) and its corresponding timeline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one regimens were added across 50 NCCN guideline document iterations during a 22-year period. The median time from when clinical data were first presented to when a regimen was first listed in the guidelines was 15 months. Phase 3 studies were conducted for 17 regimens (80%), with a surrogate endpoint (response rate or progression-free survival) as endpoint for all trials, other than one. The median time from a regimen being included in the NCCN guideline to its phase 3 data publication was 43 months. The primary endpoint was met for 13 trials (81%). No regimen was removed for a phase 3 endpoint not being met. Six regimens (38%) showed overall survival benefit. Five (23%) regimens were removed from NCCN guidelines, with none being due to failure in phase 3 testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Myeloma NCCN guidelines remain relevant and current, adding new regimens with promising early-phase data, and removing regimens that become obsolete over time. However, this process is inconsistent and may benefit from standardization.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae332","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:58:41Z","timestamp":1735059521000},"source":"Crossref","is-referenced-by-count":0,"title":["The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[{"name":"Division of Hematology, Huntsman Cancer Institute, The University of Utah ,\u00a0 Salt Lake City, UT\u00a084112 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehad","family":"Almasri","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Cincinnati ,\u00a0 Cincinnati, OH\u00a045221 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of California San Diego ,\u00a0 La Jolla, CA\u00a092093 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, University of California San Francisco ,\u00a0 San Francisco, CA\u00a094158 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, University of California San Francisco ,\u00a0 San Francisco, CA\u00a094158 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2025073103213749600_CIT0001","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA."},{"key":"2025073103213749600_CIT0002","doi-asserted-by":"publisher","first-page":"348","DOI":"10.7326\/0003-4819-150-5-200903030-00109","article-title":"Compendia and anticancer therapy under Medicare","volume":"150","author":"Tillman","year":"2009","journal-title":"Ann Intern Med."},{"key":"2025073103213749600_CIT0003","doi-asserted-by":"publisher","first-page":"635","DOI":"10.6004\/jnccn.2008.0049","article-title":"Medicare recognizes NCCN compendium","volume":"6","author":"McGivney","year":"2008","journal-title":"J Natl Compr Canc Netw."},{"key":"2025073103213749600_CIT0004","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.2016.12770","article-title":"Time to reassess the cancer compendia for off-label drug coverage in oncology","volume":"316","author":"Green","year":"2016","journal-title":"JAMA."},{"key":"2025073103213749600_CIT0005","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/annonc\/mdz232","article-title":"Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond food and drug administration approvals","volume":"30","author":"Kurzrock","year":"2019","journal-title":"Ann Oncol."},{"key":"2025073103213749600_CIT0006","doi-asserted-by":"publisher","first-page":"k668","DOI":"10.1136\/bmj.k668","article-title":"Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study","volume":"360","author":"Wagner","year":"2018","journal-title":"BMJ."},{"key":"2025073103213749600_CIT0007","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ijc.33215","article-title":"Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress","volume":"148","author":"Desai","year":"2021","journal-title":"Int J Cancer."},{"key":"2025073103213749600_CIT0008","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ajh.26166","article-title":"Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review","volume":"96","author":"Mohyuddin","year":"2021","journal-title":"Am J Hematol."},{"key":"2025073103213749600_CIT0009","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet."},{"key":"2025073103213749600_CIT0010","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet."},{"key":"2025073103213749600_CIT0011","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med."},{"key":"2025073103213749600_CIT0012","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med."},{"key":"2025073103213749600_CIT0013","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet."},{"key":"2025073103213749600_CIT0014","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"2025073103213749600_CIT0015","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"2025073103213749600_CIT0016","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica."},{"key":"2025073103213749600_CIT0017","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol."},{"key":"2025073103213749600_CIT0018","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med."},{"key":"2025073103213749600_CIT0019","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol."},{"key":"2025073103213749600_CIT0020","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet."},{"key":"2025073103213749600_CIT0021","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"2025073103213749600_CIT0022","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood."},{"key":"2025073103213749600_CIT0023","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/blood.v110.11.187.187","article-title":"Lenalidomide, bortezomib, and dexamethasone (Rev\/Vel\/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1\/2 study","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood."},{"key":"2025073103213749600_CIT0024","doi-asserted-by":"publisher","first-page":"e218084","DOI":"10.1001\/jamanetworkopen.2021.8084","article-title":"Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review","volume":"4","author":"Mohyuddin","year":"2021","journal-title":"JAMA Netw Open."},{"key":"2025073103213749600_CIT0025","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med."},{"key":"2025073103213749600_CIT0026","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood."},{"key":"2025073103213749600_CIT0027","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae332\/61272655\/oyae332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae332\/61272655\/oyae332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:21:44Z","timestamp":1753946504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae332\/7932231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae332","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,12,24]]},"article-number":"oyae332"}}